Document Detail

Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor.
MedLine Citation:
PMID:  18806523     Owner:  NLM     Status:  MEDLINE    
Ivabradine is a heart rate-lowering agent devoid of other direct cardiovascular effects that has been approved for treatment of patients with stable angina pectoris. The heart rate-lowering action of ivabradine, and its relation to clinical effects, was characterized during its development program in clinical and preclinical studies. Ivabradine selectively inhibits If in sinoatrial node cells, reducing diastolic depolarization rate and heart rate. At therapeutic concentrations, ivabradine has no action on other cardiac or vascular ion channels or receptors. Heart rate reduction with ivabradine is dose dependent and tends to a maximum or plateau level at high doses. With repeated oral dosing, the heart rate-lowering effect of ivabradine is near maximal in 2 weeks, maximal within 4 weeks, and is maintained without development of pharmacological tolerance during long-term treatment. On cessation of treatment, heart rate returns rapidly and progressively to pretreatment levels without rebound tachycardia or untoward cardiovascular events. In patients with stable angina, the reduction in heart rate is greatest in patients with the highest pretreatment heart rate, a property that should minimize the potential for ivabradine to produce excessive bradycardia. Heart rate lowering with ivabradine is associated with increases in indices of heart rate variability and causes no more than minimal changes in blood pressure. The characteristics of the heart rate-lowering action of ivabradine make it suitable for a range of patients including those for whom other antianginal agents may be contraindicated or not acceptably tolerated. They also suggest that management of treatment should be relatively simple in most patients.
Jeffrey S Borer; Jean-Yves Le Heuzey
Related Documents :
7583543 - Heightened thrombin formation but normal plasma levels of activated factor vii in patie...
10556273 - Beware of the heart: the multiple picture of cardiac involvement in myositis.
23416713 - Anesthetic considerations in infants with hypoplastic left heart syndrome.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  American journal of therapeutics     Volume:  15     ISSN:  1536-3686     ISO Abbreviation:  Am J Ther     Publication Date:    2008 Sep-Oct
Date Detail:
Created Date:  2008-09-22     Completed Date:  2008-11-04     Revised Date:  2011-06-01    
Medline Journal Info:
Nlm Unique ID:  9441347     Medline TA:  Am J Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  461-73     Citation Subset:  IM    
Cardiovascular Pathophysiology Unit and The Howard Gilman Institute for Valvular Heart Diseases, Weill Cornell Medical College, New York, NY 10128-1152, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angina Pectoris / drug therapy*,  physiopathology
Benzazepines / pharmacology*,  therapeutic use*
Blood Pressure / drug effects
Cardiovascular Agents / pharmacology*,  therapeutic use*
Clinical Trials as Topic
Cyclic Nucleotide-Gated Cation Channels / antagonists & inhibitors*
Drug Administration Schedule
Drug Interactions
Heart Rate / drug effects
Time Factors
Reg. No./Substance:
0/Benzazepines; 0/Cardiovascular Agents; 0/Cyclic Nucleotide-Gated Cation Channels; 155974-00-8/ivabradine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prevalence of use of cardiovascular drugs in 499 patients with suspected coronary artery disease at ...
Next Document:  Cardiovascular effects of psychotropic drugs.